FDA approves first topical acne treatment in children aged 9 and up

News
Article

FDA has approved the topical acne drug adapalene 0.1%/benzoyl peroxide 2.5% (Epiduo, Galderma) in children ages 9 and older, according to a news release.

FDA has approved the topical acne drug adapalene 0.1%/benzoyl peroxide 2.5% (Epiduo, Galderma) in children ages 9 and older, according to a news release.

 

Epiduo had already been approved for acne treatment in children aged 12 years and older. FDA’s more recent approval was based on data from a 12-week, multicenter, randomized, vehicle-controlled, double-blind study of pediatric patients aged 9 to 11 years. The topical treatment was found to be safe and effective, with nearly 70% of patients demonstrating improvement in acne, compared to 23% in patients treated with placebo.

Common side effects reported in the study included dry skin, erythema, skin irritation and discomfort, and a skin burning sensation.

Treating a younger population with acne could help to prevent acne scarring in the future, researchers noted.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.